|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.
|
|
2
|
Berg CD, Schiller JH, Boffetta P, Cai J,
Connolly C, Kerpel-Fronius A, Kitts AB, Lam DCL, Mohan A, Myers R,
et al: Air pollution and lung cancer: A review by international
association for the study of lung cancer early detection and
screening committee. J Thorac Oncol. 18:1277–1289. 2023. View Article : Google Scholar
|
|
3
|
Akçay S: Deciphering molecular overlaps
between COPD and NSCLC subtypes (LUAD and LUSC): An integrative
bioinformatics study. Medicine (Baltimore). 104:e439062025.
View Article : Google Scholar
|
|
4
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar
|
|
5
|
Mamdani H, Matosevic S, Khalid AB, Durm G
and Jalal SI: Immunotherapy in lung cancer: Current landscape and
future directions. Front Immunol. 13:8236182022. View Article : Google Scholar
|
|
6
|
Huang B, Song BL and Xu C: Cholesterol
metabolism in cancer: Mechanisms and therapeutic opportunities. Nat
Metab. 2:132–141. 2020. View Article : Google Scholar
|
|
7
|
Bakiri L, Hamacher R, Graña O,
Guío-Carrión A, Campos-Olivas R, Martinez L, Dienes HP, Thomsen MK,
Hasenfuss SC and Wagner EF: Liver carcinogenesis by FOS-dependent
inflammation and cholesterol dysregulation. J Exp Med.
214:1387–1409. 2017. View Article : Google Scholar
|
|
8
|
Wang X, Huang Z, Wu Q, Prager BC, Mack SC,
Yang K, Kim LJY, Gimple RC, Shi Y, Lai S, et al: MYC-regulated
mevalonate metabolism maintains brain tumor-initiating cells.
Cancer Res. 77:4947–4960. 2017. View Article : Google Scholar
|
|
9
|
Kondo A, Yamamoto S, Nakaki R, Shimamura
T, Hamakubo T, Sakai J, Kodama T, Yoshida T, Aburatani H and Osawa
T: Extracellular acidic pH activates the sterol regulatory
element-binding protein 2 to promote tumor progression. Cell Rep.
18:2228–2242. 2017. View Article : Google Scholar
|
|
10
|
He M, Zhang W, Dong Y, Wang L, Fang T,
Tang W, Lv B, Chen G, Yang B, Huang P and Xia J: Pro-inflammation
NF-κB signaling triggers a positive feedback via enhancing
cholesterol accumulation in liver cancer cells. J Exp Clin Cancer
Res. 36:152017. View Article : Google Scholar
|
|
11
|
Kloudova A, Guengerich FP and Soucek P:
The role of oxysterols in human cancer. Trends Endocrinol Metab.
28:485–496. 2017. View Article : Google Scholar
|
|
12
|
Raccosta L, Fontana R, Maggioni D,
Lanterna C, Villablanca EJ, Paniccia A, Musumeci A, Chiricozzi E,
Trincavelli ML, Daniele S, et al: The oxysterol-CXCR2 axis plays a
key role in the recruitment of tumor-promoting neutrophils. J Exp
Med. 210:1711–1728. 2013. View Article : Google Scholar
|
|
13
|
Goossens P, Rodriguez-Vita J, Etzerodt A,
Masse M, Rastoin O, Gouirand V, Ulas T, Papantonopoulou O, Van Eck
M, Auphan-Anezin N, et al: Membrane cholesterol efflux drives
tumor-associated macrophage reprogramming and tumor progression.
Cell Metab. 29:1376–1389.e4. 2019. View Article : Google Scholar
|
|
14
|
Kopecka J, Trouillas P, Gašparović AČ,
Gazzano E, Assaraf YG and Riganti C: Phospholipids and cholesterol:
Inducers of cancer multidrug resistance and therapeutic targets.
Drug Resist Updat. 49:1006702020. View Article : Google Scholar
|
|
15
|
Schabath MB, Welsh EA, Fulp WJ, Chen L,
Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, et
al: Differential association of STK11 and TP53 with KRAS
mutation-associated gene expression, proliferation and immune
surveillance in lung adenocarcinoma. Oncogene. 35:3209–3216. 2016.
View Article : Google Scholar
|
|
16
|
Castanza AS, Recla JM, Eby D,
Thorvaldsdottir H, Bult CJ and Mesirov JP: Extending support for
mouse data in the molecular signatures database (MSigDB). Nat
Methods. 20:1619–1620. 2023. View Article : Google Scholar
|
|
17
|
Wilkerson MD and Hayes DN:
ConsensusClusterPlus: A class discovery tool with confidence
assessments and item tracking. Bioinformatics. 26:1572–1573. 2010.
View Article : Google Scholar
|
|
18
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar
|
|
19
|
Barbie DA, Tamayo P, Boehm JS, Kim SY,
Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al:
Systematic RNA interference reveals that oncogenic KRAS-driven
cancers require TBK1. Nature. 462:108–112. 2009. View Article : Google Scholar
|
|
20
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar
|
|
21
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar
|
|
22
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar
|
|
23
|
Rami-Porta R, Nishimura KK, Giroux DJ,
Detterbeck F, Cardillo G, Edwards JG, Fong KM, Giuliani M, Huang J,
Kernstine KH Sr, et al: The international association for the study
of lung cancer lung cancer staging project: Proposals for revision
of the TNM stage groups in the forthcoming (ninth) edition of the
TNM classification for lung cancer. J Thorac Oncol. 19:1007–1027.
2024. View Article : Google Scholar
|
|
24
|
Ehmsen S, Pedersen MH, Wang G, Terp MG,
Arslanagic A, Hood BL, Conrads TP, Leth-Larsen R and Ditzel HJ:
Increased cholesterol biosynthesis is a key characteristic of
breast cancer stem cells influencing patient outcome. Cell Rep.
27:3927–3938.e6. 2019. View Article : Google Scholar
|
|
25
|
Turley SJ, Cremasco V and Astarita JL:
Immunological hallmarks of stromal cells in the tumour
microenvironment. Nat Rev Immunol. 15:669–682. 2015. View Article : Google Scholar
|
|
26
|
Zhang Y and Zhang Z: The history and
advances in cancer immunotherapy: Understanding the characteristics
of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 17:807–821. 2020. View Article : Google Scholar
|
|
27
|
Martínez-Jiménez F, Muiños F, Sentís I,
Deu-Pons J, Reyes-Salazar I, Arnedo-Pac C, Mularoni L, Pich O,
Bonet J, Kranas H, et al: A compendium of mutational cancer driver
genes. Nat Rev Cancer. 20:555–572. 2020. View Article : Google Scholar
|
|
28
|
Liu J, Wang X, Jiang W, Azoitei A, Eiseler
T, Eckstein M, Hartmann A, Stilgenbauer S, Elati M, Hohwieler M, et
al: Impairment of α-tubulin and F-actin interactions of GJB3
induces aneuploidy in urothelial cells and promotes bladder cancer
cell invasion. Cell Mol Biol Lett. 29:942024. View Article : Google Scholar
|
|
29
|
Otano I, Ucero AC, Zugazagoitia J and
Paz-Ares L: At the crossroads of immunotherapy for
oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol. 20:143–159.
2023. View Article : Google Scholar
|
|
30
|
Sui H, Ma N, Wang Y, Li H, Liu X, Su Y and
Yang J: Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer:
Toward personalized medicine and combination strategies. J Immunol
Res. 2018:69849482018. View Article : Google Scholar
|
|
31
|
Santoni-Rugiu E, Melchior LC, Urbanska EM,
Jakobsen JN, Stricker K, Grauslund M and Sørensen JB: Intrinsic
resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant
non-small cell lung cancer: Differences and similarities with
acquired resistance. Cancers (Basel). 11:9232019. View Article : Google Scholar
|
|
32
|
Shaw AT, Solomon BJ, Besse B, Bauer TM,
Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, et al: ALK
Resistance mutations and efficacy of lorlatinib in advanced
anaplastic lymphoma kinase-positive non-small-cell lung cancer. J
Clin Oncol. 37:1370–1379. 2019. View Article : Google Scholar
|
|
33
|
Drilon A, Siena S, Dziadziuszko R, Barlesi
F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, et al:
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer:
Integrated analysis of three phase 1–2 trials. Lancet Oncol.
21:261–270. 2020. View Article : Google Scholar
|
|
34
|
Wang Z, Zhang Q, Qi C, Bai Y, Zhao F, Chen
H, Li Z, Wang X, Chen M, Gong J, et al: Combination of AKT1 and
CDH1 mutations predicts primary resistance to immunotherapy in
dMMR/MSI-H gastrointestinal cancer. J Immunother Cancer.
10:e0047032022. View Article : Google Scholar
|
|
35
|
Wang M, Herbst RS and Boshoff C: Toward
personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 27:1345–1356. 2021. View Article : Google Scholar
|
|
36
|
King RJ, Singh PK and Mehla K: The
cholesterol pathway: Impact on immunity and cancer. Trends Immunol.
43:78–92. 2022. View Article : Google Scholar
|
|
37
|
Pavlova NN, Zhu J and Thompson CB: The
hallmarks of cancer metabolism: Still emerging. Cell Metab.
34:355–377. 2022. View Article : Google Scholar
|
|
38
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022. View Article : Google Scholar
|
|
39
|
Li J, Liu J, Liang Z, He F, Yang L, Li P,
Jiang Y, Wang B, Zhou C, Wang Y, et al: Simvastatin and
Atorvastatin inhibit DNA replication licensing factor MCM7 and
effectively suppress RB-deficient tumors growth. Cell Death Dis.
8:e26732017. View Article : Google Scholar
|
|
40
|
Mullen PJ, Yu R, Longo J, Archer MC and
Penn LZ: The interplay between cell signalling and the mevalonate
pathway in cancer. Nat Rev Cancer. 16:718–731. 2016. View Article : Google Scholar
|
|
41
|
Lee J, Jung KH, Park YS, Ahn JB, Shin SJ,
Im SA, Oh DY, Shin DB, Kim TW, Lee N, et al: Simvastatin plus
irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line
chemotherapy in metastatic colorectal patients: A multicenter phase
II study. Cancer Chemother Pharmacol. 64:657–663. 2009. View Article : Google Scholar
|
|
42
|
Liu JC, Hao WR, Hsu YP, Sung LC, Kao PF,
Lin CF, Wu AT, Yuan KS and Wu SY: Statins dose-dependently exert a
significant chemopreventive effect on colon cancer in patients with
chronic obstructive pulmonary disease: A population-based cohort
study. Oncotarget. 7:65270–65283. 2016. View Article : Google Scholar
|
|
43
|
Liu X, Lv M, Zhang W and Zhan Q:
Dysregulation of cholesterol metabolism in cancer progression.
Oncogene. 42:3289–3302. 2023. View Article : Google Scholar
|
|
44
|
Imaoka S, Yoneda Y, Sugimoto T, Hiroi T,
Yamamoto K, Nakatani T and Funae Y: CYP4B1 is a possible risk
factor for bladder cancer in humans. Biochem Biophys Res Commun.
277:776–780. 2000. View Article : Google Scholar
|
|
45
|
Wang T, Kong S, Tao M and Ju S: The
potential role of RNA N6-methyladenosine in cancer progression. Mol
Cancer. 19:882020. View Article : Google Scholar
|
|
46
|
Müller S, Glaß M, Singh AK, Haase J, Bley
N, Fuchs T, Lederer M, Dahl A, Huang H, Chen J, et al: IGF2BP1
promotes SRF-dependent transcription in cancer in a m6A- and
miRNA-dependent manner. Nucleic Acids Res. 47:375–390. 2019.
View Article : Google Scholar
|
|
47
|
Zhang L, Wan Y, Zhang Z, Jiang Y, Gu Z, Ma
X, Nie S, Yang J, Lang J, Cheng W and Zhu L: IGF2BP1 overexpression
stabilizes PEG10 mRNA in an m6A-dependent manner and promotes
endometrial cancer progression. Theranostics. 11:1100–1114. 2021.
View Article : Google Scholar
|
|
48
|
Yang B, Zhang W, Zhang M, Wang X, Peng S
and Zhang R: KRT6A promotes EMT and cancer stem cell transformation
in lung adenocarcinoma. Technol Cancer Res Treat.
19:15330338209212482020. View Article : Google Scholar
|
|
49
|
Huo Y, Zhou Y, Zheng J, Jin G, Tao L, Yao
H, Zhang J, Sun Y, Liu Y and Hu LP: GJB3 promotes pancreatic cancer
liver metastasis by enhancing the polarization and survival of
neutrophil. Front Immunol. 13:9831162022. View Article : Google Scholar
|
|
50
|
Mohammadalipour A, Showalter CA, Muturi
HT, Farnoud AM, Najjar SM and Burdick MM: Cholesterol depletion
decreases adhesion of non-small cell lung cancer cells to
E-selectin. Am J Physiol Cell Physiol. 325:C471–C482. 2023.
View Article : Google Scholar
|
|
51
|
Ngwa VM, Edwards DN, Philip M and Chen J:
Microenvironmental metabolism regulates antitumor immunity. Cancer
Res. 79:4003–4008. 2019. View Article : Google Scholar
|
